ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
12 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
1.4K
|
365K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
222 |
49K |
4 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
222
|
49K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Mainstream media is GO
|
|
pi065509
|
31 |
11K |
13 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
31
|
11K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
pi065509
|
33 |
9.0K |
9 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
33
|
9.0K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
4 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
1.4K
|
365K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
222 |
49K |
3 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
222
|
49K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
222 |
49K |
4 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
222
|
49K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
pi065509
|
100 |
28K |
15 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
100
|
28K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Big Pharma buyouts.
|
|
pi065509
|
39 |
9.7K |
8 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
9.7K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
3 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
1.4K
|
365K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
pi065509
|
58 |
15K |
22 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
58
|
15K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
pi065509
|
77 |
21K |
11 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
77
|
21K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
pi065509
|
77 |
21K |
4 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
77
|
21K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
12 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
1.4K
|
365K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
5 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
1.4K
|
365K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
12 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
1.4K
|
365K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
5 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
1.4K
|
365K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
pi065509
|
317 |
83K |
3 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
317
|
83K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
pi065509
|
317 |
83K |
4 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
317
|
83K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
pi065509
|
317 |
83K |
19 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
317
|
83K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
6 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
1.4K
|
365K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
4 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
1.4K
|
365K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
8 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
1.4K
|
365K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
pi065509
|
152 |
47K |
8 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
152
|
47K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
pi065509
|
209 |
51K |
3 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
51K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
12 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.4K
|
365K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
17 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.4K
|
365K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
16 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.4K
|
365K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
18 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.4K
|
365K
|
18
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
11 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.4K
|
365K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Outlines Pathway to Accelerated Approval for MPL in MND
|
|
pi065509
|
58 |
16K |
14 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
58
|
16K
|
14
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
12 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
1.4K
|
365K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
365K |
9 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
1.4K
|
365K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
pi065509
|
323 |
78K |
2 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
323
|
78K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
pi065509
|
323 |
78K |
6 |
04/02/24 |
04/02/24 |
ASX - By Stock
|
323
|
78K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
pi065509
|
323 |
78K |
17 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
323
|
78K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
pi065509
|
323 |
78K |
15 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
78K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
111K |
6 |
26/01/24 |
26/01/24 |
ASX - By Stock
|
430
|
111K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
111K |
9 |
23/01/24 |
23/01/24 |
ASX - By Stock
|
430
|
111K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
111K |
9 |
23/01/24 |
23/01/24 |
ASX - By Stock
|
430
|
111K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
111K |
20 |
23/01/24 |
23/01/24 |
ASX - By Stock
|
430
|
111K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
111K |
9 |
16/01/24 |
16/01/24 |
ASX - By Stock
|
430
|
111K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Grants PharmAust Pre-IND Meeting
|
|
pi065509
|
61 |
17K |
14 |
08/01/24 |
08/01/24 |
ASX - By Stock
|
61
|
17K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Grants PharmAust Pre-IND Meeting
|
|
pi065509
|
61 |
17K |
6 |
07/01/24 |
07/01/24 |
ASX - By Stock
|
61
|
17K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Grants PharmAust Pre-IND Meeting
|
|
pi065509
|
61 |
17K |
20 |
06/01/24 |
06/01/24 |
ASX - By Stock
|
61
|
17K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
111K |
13 |
05/01/24 |
05/01/24 |
ASX - By Stock
|
430
|
111K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
111K |
7 |
05/01/24 |
05/01/24 |
ASX - By Stock
|
430
|
111K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FightMND Invites PharmAust to Apply for Phase 2/3 Funding
|
|
pi065509
|
56 |
15K |
5 |
30/12/23 |
30/12/23 |
ASX - By Stock
|
56
|
15K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
111K |
7 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
430
|
111K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
111K |
5 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
430
|
111K
|
5
|
|